ISRG — Intuitive Surgical, Inc.

Is ISRG overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Oversold As of November 17, 2026

Intuitive Surgical, Inc. (ISRG) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $437.75. The rating moved from Neutral to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Intuitive Surgical remains the dominant player in robotic-assisted surgery with a strong installed base and recurring consumable/service revenues that support steady cash flow and R&D investment. Growth is supported by continued adoption across more procedures, international expansion, and new platform rollouts, while a healthy balance sheet allows for strategic execution. Near-term market conditions are supportive of capital-equipment decisions, but outcomes hinge on execution of product launches, hospital purchasing cycles, and procedure utilization. Key vulnerabilities include intensifying competition, reimbursement and regulatory risks, capital spending cyclicality, and valuation sensitivity which could amplify downside if growth disappoints. Overall, the company’s structural advantages and revenue visibility present a favorable multi-quarter outlook, contingent on continued execution and stable macro/hospital demand.

Key factors

  • Market leadership in robotic-assisted surgery with a durable installed base and high switching costs for hospitals
  • Recurring high-margin consumable and service revenue stream that supports steady aftermarket earnings
  • Strong balance sheet and cash generation enabling R&D investment, product launches, and potential M&A
  • Ongoing expansion into new procedures and specialties (e.g., single-port, thoracic, general surgery) driving TAM growth
  • International rollout and upgrade cycles in developed and emerging markets provide multi-year revenue runway
  • Favorable near-term market tone (measured risk-on) that supports capital-equipment spending decisions by hospitals
  • Execution on new platforms and software improvements could drive share gains and higher utilization of installed units
  • Relatively limited short-term headline macro or geopolitical shocks in the recent trading window, reducing volatility

Risks

  • Intensifying competition from large medtech peers (e.g., Medtronic, J&J) and new robotic entrants that could pressure pricing and share
  • Cyclical hospital capital spending and procedure volumes can slow system placements and attach-rate growth
  • Regulatory, safety or device-related recalls could materially affect utilization and reputation
  • Reimbursement pressures or changes in payer policies that reduce hospital economics for robotic procedures
  • Valuation sensitivity: highly priced growth expectations could lead to sharp downside on earnings disappointments
  • Supply-chain disruption or manufacturing constraints that delay system shipments or accessory availability
  • Political or policy-driven shifts (e.g., healthcare cost containment) that alter hospital purchasing behavior
  • Potential litigation or product liability actions that could increase costs or restrict operations

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ISRG — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.